Integrated Fluidic Circuits Enable Advances in Life Science Research
News May 27, 2009
The Spring 2009 edition of the e-newsletter - IFC Application Hotspot from the Fluidigm Corporation is now available free to download from www.fluidigm.com/newsletters/2009edition1/index.html.
The IFC Application Hotspot is a quick source for the latest news on how integrated fluidic circuits (IFCs) are enabling ground breaking advances in life science research. In each edition - Fluidigm report upon new products, applications innovations, and customer advances using revolutionary IFC technology.
The latest issue reports upon easy methods to genotype copy number variants using nanofluidics and PCR. Recent experiments demonstrate the versatility of Dynamic Arrays in measuring gene copy number variations with unparalleled throughput and sensitivity. A review of the recently published customer article 'Fetal Aneuploidy detection from cell-free DNA and maternal plasma RNA' article provides a valuable independent insight into the underlying benefits of digital PCR technology.
According to Company, the new technology developments describe how the new Fluidigm Slingshot kit allow users to achieve DNA library concentration for next generation sequencing - without the need for titration runs, reference samples, or mass bias calibrators. An informative introduction is also provided for the new 48.770 Digital Array. The highest density integrated fluidic circuit (IFC) ever, the new 48.770 Digital Array generates almost 37,000 individual qPCR reactions and provides 48 individual sample inlets.
Researchers from the Spanish National Cancer Research Centre (CNIO) have shown in a new study that the gene therapy with telomerase that they have developed, and which has proven to be effective in mice against diseases caused by excessive telomere shortening and ageing, does not cause cancer or increase the risk of developing it, even in a cancer-prone setting.READ MORE
Scientists report a novel gene therapy that halts vision loss in a canine model of a blinding condition called autosomal dominant retinitis pigmentosa (adRP). The strategy could one day be used to slow or prevent vision loss in people with the disease. NEI is part of the National Institutes of Health.